Not helping matters either was a downbeat full year forecast - the firm warning that 'very challenging' market conditions - due to weather hit Western European markets - will have an impact.
Standard Life put on 11.25 to 326.25 - the lifeco posting a City-beating 31% rise in H1 sales to £8.18 billion.
UK sales meanwhile jumped 45% to £6.95 billion, prompted by an 82% gain in individual self-invested personal pension SIPP business more than offsetting a drop in traditional individual pensions sales.
The insurer said it expects to report a 'significant increase' in sales margins next month, given the SIPPs business is fundamentally more profitable than traditional pensions business.
Tesco rose 9 to 418.25 - Deutsche Bank raising its recommendation on the food retailing giant from 'hold' to 'buy' - arguing the firm's US business could be worth at least 20p per share.
EasyJet put on 36 to 544 - the no-frills air carrier reporting a 5.7% rise in Q3 revenues to £486.5 million. But revenue per seat slipped 8% to £41.46.
However, the firm reiterated full year guidance for the year to September 2007 of pre-tax profit growth in the range of 40%-50%.
GW Pharmaceuticals hardened 2.38 to 72.38 - the firm announcing that Health Canada has approved Sativex - its cannabis derived pharmaceutical treatment - as an adjunctive analgesic treatment in adult patients with advanced cancer.
Sativex, the only pharmaceutical product derived from components of the cannabis plant, is administered through a spray into the patient's mouth.
In 2005, Health Canada approved Sativex for the treatment of neuropathic pain in adults with multiple sclerosis MS.
Moneyextra.com recommends you take independent financial advice before acting on any article
Back2007-08-07 16:51:55 © Moneyextra.com